Media Summary: Earn CME credit for a related activity: In this presentation from Lymphoma & Myeloma 2018, Dr. In this presentation from the Lymphoma & Myeloma 2017, Dr. Joseph R. Mikhael discusses whether Adriana Rossi, MD, Weill Cornell Medical College, New York City, NY, discusses on B-cell maturation (BCMA) targeted

Anti Cd38 Slamf 7 And Bite Immunotherapy Are Immune Therapeutics Ready For The Frontline - Detailed Analysis & Overview

Earn CME credit for a related activity: In this presentation from Lymphoma & Myeloma 2018, Dr. In this presentation from the Lymphoma & Myeloma 2017, Dr. Joseph R. Mikhael discusses whether Adriana Rossi, MD, Weill Cornell Medical College, New York City, NY, discusses on B-cell maturation (BCMA) targeted Earn CME: In this webcast from the 'Multiple Myeloma: Treatment Challenges and ... Multiple myeloma (MM) is at the forefront of Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, presents findings from a Phase II trial (NCT04835129) ...

Saad Usmani, MD, University of North Carolina School of Medicine, Chapel Hill, NC, discusses Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, gives an overview of the monoclonal ... Leo Rasche, MD, University of Arkansas for Medical Sciences, Little Rock, AR, gives an update on the role of elotuzumab, which ... James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, discusses a study ... Michael O'Dwyer, MD, PhD, National University of Ireland, Galway, Ireland, discusses how Watch this Impressive footage as one of our

Lipids have long been used as drug delivery vehicles, but HighField Biopharmaceutics is repurposing lipids as drugs to fight ... David A. Braun, MD, PhD, Yale School of Medicine, New Haven, CT, explains how a transitional study used advanced genomic ... Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the importance of monoclonal antibodies for multiple ... During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Andrew M. Amrita Krishnan, MD, City of Hope Medical Center, Duarte, CA, discusses the preliminary results from a Phase Ib study ...

Photo Gallery

Anti CD38, SLAMF-7 and BiTE immunotherapy: Are immune therapeutics ready for the frontline?
Anti CD38 and anti SLAMF7 Therapeutics: Are they ready to go upfront?
MM: Are anti-BCMA immunotherapies ready for the frontline?
Antibodies in Practice: SLAMF-7, CD38, Bispecific?
Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs
Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myeloma
CD38: a promising target for multiple myeloma antibody therapy
CD38 and SLAMF7 targeting for multiple myeloma
SLAMF7 as a target for multiple myeloma
Dr. Berenson on Arming an Anti-CD38 Antibody With Interferon in Myeloma
Anti-CD38 CAR NK-cells: an off-the shelf therapy for multiple myeloma
Bispecific T-Cell Engager (BiTE) Therapy
Sponsored
Sponsored
View Detailed Profile
Anti CD38, SLAMF-7 and BiTE immunotherapy: Are immune therapeutics ready for the frontline?

Anti CD38, SLAMF-7 and BiTE immunotherapy: Are immune therapeutics ready for the frontline?

Earn CME credit for a related activity: https://www.naccme.com/oln In this presentation from Lymphoma & Myeloma 2018, Dr.

Anti CD38 and anti SLAMF7 Therapeutics: Are they ready to go upfront?

Anti CD38 and anti SLAMF7 Therapeutics: Are they ready to go upfront?

In this presentation from the Lymphoma & Myeloma 2017, Dr. Joseph R. Mikhael discusses whether

Sponsored
MM: Are anti-BCMA immunotherapies ready for the frontline?

MM: Are anti-BCMA immunotherapies ready for the frontline?

Adriana Rossi, MD, Weill Cornell Medical College, New York City, NY, discusses on B-cell maturation (BCMA) targeted

Antibodies in Practice: SLAMF-7, CD38, Bispecific?

Antibodies in Practice: SLAMF-7, CD38, Bispecific?

Earn CME: https://www.naccme.com/program/19-lm-05 In this webcast from the 'Multiple Myeloma: Treatment Challenges and ...

Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs

Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs

Multiple myeloma (MM) is at the forefront of

Sponsored
Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myeloma

Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myeloma

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, presents findings from a Phase II trial (NCT04835129) ...

CD38: a promising target for multiple myeloma antibody therapy

CD38: a promising target for multiple myeloma antibody therapy

Saad Usmani, MD, University of North Carolina School of Medicine, Chapel Hill, NC, discusses

CD38 and SLAMF7 targeting for multiple myeloma

CD38 and SLAMF7 targeting for multiple myeloma

Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, gives an overview of the monoclonal ...

SLAMF7 as a target for multiple myeloma

SLAMF7 as a target for multiple myeloma

Leo Rasche, MD, University of Arkansas for Medical Sciences, Little Rock, AR, gives an update on the role of elotuzumab, which ...

Dr. Berenson on Arming an Anti-CD38 Antibody With Interferon in Myeloma

Dr. Berenson on Arming an Anti-CD38 Antibody With Interferon in Myeloma

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, discusses a study ...

Anti-CD38 CAR NK-cells: an off-the shelf therapy for multiple myeloma

Anti-CD38 CAR NK-cells: an off-the shelf therapy for multiple myeloma

Michael O'Dwyer, MD, PhD, National University of Ireland, Galway, Ireland, discusses how

Bispecific T-Cell Engager (BiTE) Therapy

Bispecific T-Cell Engager (BiTE) Therapy

Bispecific T-Cell engager (

Activated T cell attacks a cancer cell

Activated T cell attacks a cancer cell

Watch this Impressive footage as one of our

Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies

Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies

Lipids have long been used as drug delivery vehicles, but HighField Biopharmaceutics is repurposing lipids as drugs to fight ...

Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?

Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?

As we learn more about

The role of SLAMF7-positive, CD8-positive T-cells in therapeutic resistance in kidney cancer

The role of SLAMF7-positive, CD8-positive T-cells in therapeutic resistance in kidney cancer

David A. Braun, MD, PhD, Yale School of Medicine, New Haven, CT, explains how a transitional study used advanced genomic ...

The importance of anti-CD38 monoclonal antibodies for multiple myeloma

The importance of anti-CD38 monoclonal antibodies for multiple myeloma

Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the importance of monoclonal antibodies for multiple ...

Why is TIM3 a good target for treating patients with high-risk MDS?

Why is TIM3 a good target for treating patients with high-risk MDS?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Andrew M.

Mezagitamab: an anti-CD38 antibody for R/R MM

Mezagitamab: an anti-CD38 antibody for R/R MM

Amrita Krishnan, MD, City of Hope Medical Center, Duarte, CA, discusses the preliminary results from a Phase Ib study ...